Pharmacologic Principles

The action of the medication will begin sooner when given intravenously. Intravenous administration allows direct entry into the bloodstream, facilitating rapid distribution and onset of therapeutic effects compared to oral medications, which must undergo digestion and absorption. A: The medication will cause fewer adverse effects when given intravenously. While intravenous administration can minimize certain effects, it does not inherently reduce adverse effects compared to other routes. B: The intravenous medication will have delayed absorption into the body's tissues. In fact, intravenous medications are absorbed immediately, providing a swift therapeutic response rather than a delayed effect. D: There is a lower chance of allergic reactions when drugs are given intravenously. Allergic reactions can occur regardless of the route of administration; intravenous delivery does not inherently lessen this risk.

Parenteral drugs bypass the first-pass effect. This is significant because these drugs are administered directly into the bloodstream or tissues, allowing them to avoid metabolism by the liver before reaching systemic circulation, leading to quicker therapeutic effects. B: Absorption of parenteral drugs is affected by reduced blood flow to the stomach. Parenteral administration does not involve the gastrointestinal tract, thus making stomach blood flow irrelevant to drug absorption. C: Absorption of parenteral drugs is faster when the stomach is empty. Since parenteral drugs do not rely on the digestive system, the state of the stomach does not influence their absorption rate. D: Parenteral drugs exert their effects while circulating in the bloodstream. While they do circulate in the bloodstream, effectiveness is not solely dependent on circulation but also on the specific site of action.

The patient is experiencing a pharmacologic reaction. This type of adverse drug reaction occurs when the effects of a medication are predictable and directly related to its pharmacological properties, as seen with low blood pressure and lethargy. A: Adverse effect A general term that encompasses any unintended consequences of a drug, but does not specifically address the predictable nature of the patient's symptoms related to the medication's action. B: Allergic reaction This involves an immune response to a drug, typically manifesting as rashes or anaphylaxis, which does not align with the lethargy and hypotension observed in this patient. C: Idiosyncratic reaction This refers to unusual responses that are not predictable based on the drug's known effects and mechanisms. The symptoms presented are consistent with the drug's pharmacological actions, not idiosyncratic.

A: The time it takes for the drug to cause half of its therapeutic response. This statement misinterprets half-life, which specifically refers to the duration required for drug elimination, not therapeutic effects. B: The time it takes for one half of the original amount of a drug to reach the target cells. This option confuses pharmacokinetics with pharmacodynamics, focusing on distribution rather than elimination, which defines half-life. D: The time it takes for one half of the original amount of a drug to be absorbed into the circulation. This description pertains to absorption rather than the elimination process, which is central to understanding half-life.

The duration of action of a drug is the time period at which a drug's concentration is sufficient to cause a therapeutic response. This definition emphasizes the importance of maintaining adequate drug levels to achieve the desired clinical effects over time. A: The time it takes for a drug to elicit a therapeutic response focuses on the onset rather than the sustained effect, which is not the definition of duration. B: The amount of time needed to remove a drug from circulation pertains to elimination rather than the period of effective therapeutic concentration, which does not define duration of action. C: The time it takes for a drug to achieve its maximum therapeutic response refers to the peak effect, rather than the overall time the drug remains effective in the system.

The drug binds to an enzyme molecule and inhibits or enhances the enzyme's action with the normal target cell. This describes selective enzyme interaction, emphasizing the drug's specific influence on enzyme activity, crucial for therapeutic efficacy. A: The drug alters cell membrane permeability. This describes a different mechanism, focusing on changing how substances enter or exit cells rather than interacting specifically with enzymes. B: The drug's effectiveness within the cell walls of the target tissue is enhanced. This statement implies a generalized improvement in drug action but does not detail the specific mechanism involving enzymes. C: The drug is attracted to a receptor on the cell wall, preventing an enzyme from binding to that receptor. This option suggests receptor blockade rather than the direct modulation of enzyme function, which is not the focus of selective enzyme interaction.

The duration of action of the medication will be longer. Highly protein-bound medications remain in circulation longer due to their binding to albumin, which slows their release and metabolism, resulting in extended effects. A: Renal excretion will be faster. Highly protein-bound drugs are not readily filtered by the kidneys, leading to slower renal excretion rates compared to less protein-bound medications. B: The drug will be metabolized quickly. Drugs that are highly protein-bound typically undergo slower metabolism due to their prolonged presence in the bloodstream, delaying their breakdown. C: The duration of action of the medication will be shorter. Medications that are highly protein-bound are retained longer in the system, thus extending their duration of action rather than shortening it.

The tablet should be placed in the space between the cheek and the gum. This method allows the nitroglycerin to be absorbed quickly into the bloodstream, providing rapid relief from chest pain. A: Under the tongue. This location is typical for sublingual medications, but buccal administration specifically targets absorption through the cheek area for this formulation. B: On top of the tongue. Placing the tablet here would hinder absorption, as the medication needs to be in contact with the mucous membranes for effective delivery. C: At the back of the throat. This placement would impede absorption and could lead to swallowing the tablet rather than allowing it to dissolve properly in the mouth.

D: Excretion. Patients with end-stage renal disease experience significant challenges in excretion, as their kidneys are unable to effectively remove waste products and medications from the bloodstream, leading to potential toxicity. A: Absorption. While absorption can be affected by various factors, kidney failure primarily impacts the elimination of substances rather than their initial absorption from the gastrointestinal tract. B: Distribution. Distribution involves how drugs are dispersed throughout the body, which is generally influenced by factors such as blood flow and protein binding, not directly related to kidney function. C: Metabolism. Although metabolism is crucial for drug processing, it primarily occurs in the liver, making it less impacted by renal failure compared to the excretion phase of pharmacokinetics.

Palliative therapy encompasses the administration of medications aimed at alleviating suffering and enhancing comfort for patients with terminal conditions, such as advanced cancer, without focusing on curing the illness. B: Maintenance therapy This term refers to treatments aimed at sustaining a patient's health status rather than providing comfort during terminal stages, which does not apply in this context. C: Empiric therapy This pertains to treatment based on clinical experience or best guesses rather than established protocols, lacking relevance to the supportive care needed in end-of-life situations. D: Supplemental therapy This describes additional treatments that support primary therapies, not the primary focus on comfort and pain relief necessary for patients nearing the end of life.

C: A powder. Powders dissolve quickly in liquid, leading to rapid absorption into the bloodstream, which enhances the onset of pain relief. This makes powders the fastest acting over-the-counter option for headache relief. A: A capsule. Capsules may take longer to dissolve in the stomach, delaying the release of medication and subsequently prolonging the time before pain relief is felt. B: A tablet. Tablets require disintegration before absorption can occur, which typically results in a slower onset of action compared to powders, making them less effective for immediate headache relief. D: An enteric-coated tablet. Enteric-coated tablets are designed to dissolve in the intestines rather than the stomach, which can significantly slow the onset of action and delay pain relief for headaches.

Intradermal. This route involves injecting medication into the dermis, which lies just beneath the epidermis. This method is commonly used for allergy tests and some vaccinations, allowing for localized responses. B: Subcutaneous. This method involves administering medication into the fat layer beneath the skin, not specifically targeting the dermis directly underneath the epidermal layer. C: Intramuscular. This technique injects medication deep into muscle tissue, which is significantly deeper than the superficial skin layers described in the question. D: Transdermal. This approach delivers medication through the skin's surface into the bloodstream, bypassing the need for injections and does not involve direct skin layer injection.

C, D, F. Drugs administered orally will undergo the first-pass effect, where a significant portion is metabolized by the liver before reaching systemic circulation. This impacts their bioavailability and therapeutic effectiveness. A: Morphine given by IV push injection. Intravenous administration bypasses the digestive system and liver, allowing direct entry into the bloodstream, avoiding any first-pass metabolism. B: Sublingual nitroglycerin tablet. The sublingual route allows for rapid absorption into the bloodstream, circumventing the digestive system and liver, thus not subject to the first-pass effect. E: Transdermal nicotine patches. This route delivers medication through the skin directly into circulation, avoiding the gastrointestinal tract and liver metabolism, hence not influenced by the first-pass effect. G: Penicillin given by IV piggyback infusion. Similar to morphine, intravenous delivery allows immediate access to systemic circulation, thereby negating any first-pass effect related to oral administration.

5 mg After one half-life of 5 hours, the amount of drug in the body is reduced by half. Starting with 10 mg, only 5 mg remains, demonstrating the concept of half-life effectively. A: 10 mg This choice suggests that the entire initial dose remains after 5 hours, contradicting the fundamental principle of half-life where the quantity decreases by half. B: 2.5 mg This option implies a further reduction beyond one half-life, which misinterprets the calculation; only one half-life has occurred, resulting in 5 mg remaining. C: 1 mg This choice indicates a significantly lower amount than expected after one half-life, failing to recognize that the reduction process only halves the initial dose, not further diminishes it.